Abstract: The disclosure is directed to sorbent compositions for removing reduced sulfur species (e.g., H2S, COS and CS2) a feed stream. The sorbent is formed from a multi-phase composition including a zinc titanate phase and a zinc oxide-aluminate phase. The sorbent composition is substantially free of unreacted alumina.

Abstract: The invention provides, improved herbicide compositions, methods of making the compositions and methods of controlling plant growth. The subject invention relates to combining fatty acid based and other herbicides with succinic acid, succinic acid derivatives and other additives such as those having essentially no herbicidal activity to increase the activity of the herbicide and provide methods of controlling plant growth by applying a combination of a herbicidal fatty acid with succinic acid and/or succinic acid derivative chemicals and/or other additives. In addition to the use of succinic acid, combining other Krebs cycle acids with herbicides can also provide beneficial effects. Concentrations of herbicides and additives applied to plants in accordance with the invention can include compositions involving 0.1 to 30% herbicide, preferably 0.5 to 15% herbicide and additive and more preferably 1-8% herbicide.

Abstract: Superconductive bodies composed of cuprate material having a very critical current density with outer magnetic fields of up to 5 tesla when the bodies have a content of zinc cations. The bodies can also be subjected to modified oxygen treatment. The preferred cuprate materials are YBCO material and bismuth oxide based on superconductive material such as “2212” or “2223” type superconductive material. The preferred bodies are molded bodies obtained by melt texturing and “powder-in-tube” bodies.

Abstract: A foaming composition for topical application, comprising at least one surfactant system comprising at least one fatty acid chosen from partially and completely neutralized fatty acids, at least one non-betaine amphoteric co-surfactant and at least one anionic co-surfactant of the sulphosuccinate type and its use in the cosmetic or dermatological fields, for example, as cleansing and/or make-up-removing products for a human keratinous material, for example, the skin.

Abstract: Slurry compositions comprising an oxidizing agent, optionally a copper corrosion inhibitor, abrasive particles; surface active agent, a service of chloride and a source of sulfate ions.

Abstract: The present invention is directed to cleaning compositions for metal surfaces, including both concentrates and ready-to-use solutions. These compositions include a source of calcium ion, a source of alkalinity, a chelating agent, and a surfactant. In some embodiments, a water-soluble or water-dispersible acid-substituted polymer is also included. Additionally, in some embodiments, specific surfactants or chelating agents are used to enhance the performance of the composition.

Abstract: The present invention is directed to a grease-cutting detergent composition that exhibits a stable foaming profile when used with non-enclosed automatic dishwashers. The composition can be sold in a concentrated form or in ready-to-use (RTU) diluted form. The concentrated compositions are formulated to be diluted with water before use. The RTU formulas are intended for as-is usage. In one embodiment the concentrated compositions comprises a) from about 0.25% to about 10% of a surfactant, b) from about 4% to about 8% of an alkalinity source, c) from about 0.1% to about 4.0% of a hydrotrope, d) from about 0.001% to about 2.0% of a builder, and e) from about 0.01% to about 3.0% of a thickener. In another embodiment an RTU formulation comprises a) from about 50 ppm to about 80 ppm of a surfactant, b) from about 45 ppm to about 75 ppm of an alkalinity source, c) from about 20 ppm to about 45 ppm of a hydrotrope, d) from about 0.

Abstract: A method of substantially reducing biofilm-associated microorganisms on a surface and a composition designed to substantially reduce biofilm-associated microorganisms on surfaces are disclosed. In one embodiment, the composition is an anionic surfactant selected from the group consisting of alkyl sulfates, alkyl sulfonates, and aryl sulfonates with alkyl or aryl substituents, an acid, and an alcohol solvent, wherein the pH of the composition is between pH 1 and pH 5.

Abstract: The invention provides an iron-based cleaning powder capable of efficiently decomposing organic halides. The iron-based cleaning powder is made of iron alloy powder or iron powder produced with an atomization process. The iron alloy powder passes a 300 &mgr;m-mesh sieve at a proportion of not less than 90% and has an H2-reduction mass loss of 0.1 to 0.8% when it contains 0.3 to 1.1% of Mn. When the iron alloy powder contains 0.2 to 12% of Ni, it has an H2-reduction mass loss of 0.1 to 1.0%. The iron powder is used as mixed powder or partially alloyed powder together with Ni-containing powder. The iron powder passes a 300 &mgr;m-mesh sieve at a proportion of not less than 90% and has an H2-reduction mass loss of 0.1 to 1.0%. The Ni-containing powder has a Ni content of not less than 40% and passes a 45 &mgr;m-mesh sieve at a proportion of not less than 90%. The iron alloy powder and the iron powder have a martensite structure or a tempered martensite structure.

Abstract: The present invention relates to hydrophobically modified polyamines and laundry detergent compositions which comprise said polyamines, said compositions comprising: A) from about 0.01%, preferably from about 0.

Abstract: The present invention relates to a method for treating material with a treatment composition in a water-soluble pouch, whereby firstly a part of the composition is applied to the material by partially opening the pouch to allow dispensing of part of the treatment composition, and subsequently the material and the remaining of the pouched composition are washed in water. Preferred is a method whereby the pouch has at least two compartments and one compartment, comprising a liquid composition, is opened and the liquid composition is rubbed onto the material or preferably fabric, where after the remaining of the pouch (including the still closed compartment and composition therein) are added to the wash water, for example a washing machine.

Abstract: A process for coating laundry detergent or cleaning product tablets that contain builder(s) and also, if desired, further laundry detergent and cleaning product ingredients, by transporting the tablets on a conveyor belt provided with a multiplicity of apertures and forcing coating material through the conveyor belt apertures from below with a force such that the coating material forced over the conveying plane forms a surge through which the tablets are transported.

Abstract: Surfactant mixtures comprising (a) a nonionic surfactant mixture present in an amount greater than 60% by weight, based on the weight of the surfactant mixture, the nonionic surfactant mixture comprising: (i) at least one alk(en)yl oligoglycoside of the general formula (I), R1O—[G]p  (I) wherein R1 represents an alk(en)yl radical having from 4 to 22 carbon atoms, G represents a sugar radical having 5 or 6 carbon atoms and p represents a number from 1 to 10; and (ii) at least one nonionic surfactant of the general formula (II) R2O(CH2CHRO)xH  (II) wherein x represents a number of from 1 to 30, each R independently represents a substituent selected from the group consisting of a hydrogen, a methyl group and an ethyl group, and R2 represents a linear alkyl radical having from 16 to 22 carbon atoms; and (b) up to 6% by weight, based on the weight of the surfactant mixture, of one or more anionic surfactants; are described.

Abstract: The invention relates to a highly alkaline or mildly alkaline detergent composition having enhanced cleaning properties. The detergent combines a source of alkalinity and a blend of nonionic surfactants that enhances cleaning starchy soils. The blend of nonionic surfactants preferably includes an alkyl polyglycoside surfactant and a silicon surfactant having a hydrophobic silicon group and a pendant hydrophilic group. Preferably, the blend of nonionic surfactants includes a surfactant having a hydrophobic group and an ethylene oxide residue containing group and a polymer additive. A method for removing soil from an article is provided.

Abstract: The present invention relates to novel proteins interacting with the cytoplasmic domain of CD40, which are useful in the treatment of CD40 and/or NF-kB related diseases. Surprisingly, these proteins do not show significant homology with the TRAF-protein family and therefore offer the possibility to modulate the CD40 and/or NF-kB pathway independently from the TRAF-CD40 interaction.

Abstract: The invention relates to a method for selectively releasing an agent loaded into a red blood cell, comprising electrosensitizing the red blood cell by application of an electric field and subsequently disrupting the cell selectively using ultrasound.

Abstract: Disclosed herein are methods for treating vascular disorders in mammals. The methods involve administering one or more agents selected from the group consisting of a heat shock protein (HSP), a therapeutically effective fragment and a therapeutically effective analog of a heat shock protein in a form suitable for mucosal administration. In some embodiments the heat shock protein of the method is mycobacterial HSP65. In some embodiments the heat shock protein is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The method is of particular value in the treatment of atherosclerosis. Also disclosed are compositions useful for treating vascular disorders in mammals. The compositions include one or more agents selected from the group consisting of heat shock protein, therapeutically effective fragments and therapeutically effective analogs of said heat shock protein in aerosol or oral form. In some embodiments the heat shock protein of the composition is mycobacterial HSP65.

Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.

Abstract: The present invention relates to methods of reducing heme loss in hemoglobins to produce stability and improve expression yield of hemoglobins, particularly recombinant hemoglobins. Such methods are accomplished by introducing mutations in the alpha or beta subunits of hemoglobins to increase heme affinity. The present invention further relates to novel mutations that reduce such heme loss.

Abstract: A method for treatment or prophylaxis of a patient suffering from functional symptoms of Parkinson's disease, especially as a consequence of damage to dopaminergic neurons, by administering to the patient a neuroprotective amount of a peptide selected from the tripeptide gly-pro-glu (GPE) and analogs and mimetics thereof, preferably GPE. The GPE will usually be administered subsequent to the onset of Parkinson's disease but prior to the damage of said dopaminergic neurons.

Abstract: This invention relates to a conjugate which consists of an active substance and a native protein which is not regarded as exogenous and distinguish itself in that an intracellulary cleavable linker is present between the active substance and the protein. In addition, this invention concerns a process for the preparation of such a conjugate and its use.

Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.

Abstract: This invention relates to a method and compositions for treating pathological intervertebral discs comprising the step of delivering an agent that causes chemical crosslinking of the native molecular components of the disc. Supplemental materials which are susceptible to crosslinking by the aforementioned agent are optionally delivered to the disc in order to increase and maintain disc height.

Abstract: There is provided a method of assessing oxidant stress by measuring polymerization of proteins. Also provided is a marker for oxidant stress which includes a polymerized protein. A kit for use in assessing oxidant stress, the kit including an assay for detecting polymerized proteins is also provided. A method of lowering oxidant stress by administering to a patient an effective amount of at least one reducing agent is also provided. A pharmaceutical composition for lowering oxidant stress, the pharmaceutical having an effective amount of reducing agent and a pharmaceutically acceptable carrier is also provided.

Abstract: The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.

Abstract: In the present invention, it is discovered that a compound of formula (I) has a potent effect for treatment of osteoporosis, arthritis and ruptured disc: in which R1 represents hydrogen atom or alkyl group and R2 represents hydrogen atom r cinnamoyl group. Therefore, the compound of formula (I) can be used for prevention and treatment of osteoporosis, arthritis and ruptured disc. Thus, the present invention provides a pharmaceutical preparation containing as an effective component a compound of formula (I) in combination with a pharmaceutically acceptable auxiliary, diluent, isotonic agent, preservative, lubricant and solubilizing aid, which is formulated in the form of a pharmaceutically acceptable preparation and has a potent effect for osteoporosis, arthritis and ruptured disc.

Abstract: Compositions and pharmaceutical compositions are described which comprise: a component A comprising one or more flavonol glycosides, a component B comprising one or more tetrahydrofolic acid compounds, a component C comprising one or more calcium supplements, and a component D comprising one or more magnesium supplements. Methods of using such compositions and pharmaceutical compositions to treat and/or prevent osteoporosis and/or an inflammatory joint disease are also described.

Abstract: There are described 11-C-substituted derivatives of clarithromycin and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds.

Abstract: The present invention provides a medical device that includes a carrier and a polynucleotide, where the carrier has a surface that includes a polymer with which the polynucleotide is associated. In another aspect, the present invention provides a medical device that includes a carrier and a cell that expresses an antimicrobial peptide, where the carrier has a surface that includes a polymer with which the cell is associated. The present invention further provides methods of making and using medical devices that include a carrier and a polynucleotide or a cell.

Abstract: The present invention relates to novel compounds which make it possible to transfer nucleic acids into cells. These novel compounds are lipid derivatives of polythiourea. They are useful for the in vitro, ex vivo or in vivo transfection of nucleic acids into various cell types.

Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Abstract: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Abstract: The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoagulant heparan sulfate onto an affinity matrix and separating the non-bound material from the bound material. The affinity matrix is made of a fibroblast growth factor immobilized on a support. The invention also relates to a method and composition for neutralizing anticoagulation catalyzed by heparin, a heparin mimic, or a heparin derivative, by contacting heparin, a heparin mimic, or a heparin derivative with a fibroblast growth factor.

Abstract: The present invention relates to a peritoneal dialysis solution comprising at least one amino sugar in an effective amount sufficient to create an osmotic pressure to effect the removal of water by diffusion from the patient's blood across the peritoneal membrane into the solution. In one embodiment the at least one amino sugar is selected from the group consisting of acetylated amino sugars, preferably N-acetylglucosamine, deacetylated amino sugars and combinations thereof.

Abstract: The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.

Abstract: Use of phosphorous organic compounds of general formula (I) wherein B represents either an ether group of the formula (II) or a keto group of the formula (III) or is a 5 or 6 membered cyclic compound, and their use for preparing pharmaceutical compositions for the therapeutic and prophylactic treatment of infections in humans and animals due to viruses, bacteria, fungi, and parasites as well as their use as a fungicide, bactericide and herbicide in plants.

Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: Benzoxazines of Formula (I) wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, or (CH2)n phenyl, R2 is C3-C6 alkyl, R3 is hydrogen, halo, hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, or a pharmaceutically acceptable salt thereof, are useful for treating movement disorders such as Parkinson's disease.

Abstract: It is to provide a novel fungicide having high controlling effects on plant diseases particularly on wheat powdery mildew and cucumber gray mold, without ill effects on crops. A carbamate derivative represented by the general formula [I] {wherein X is a halogen atom, a C1-C6 alkyl group or the like, n is 0 or an integer of from 1 to 4, R1 is a C1-C6 alkyl group, R2 is a hydrogen atom, a C1-C6 alkyl group or the like, R3 is a hydrogen atom or a C1-C6 alkyl group, G is an oxygen atom, a sulfur atom or the like, Y is a hydrogen atom, a C1-C10 alkyl group, C2-C10 alkenyl group or the like, and Q is a hydrogen atom, a C1-C6 haloalkyl group, a phenyl group or the like} and an agricultural/horticultural fungicide containing the same as the active ingredient.

Abstract: This invention is directed to pharmaceutical compositions useful in treating progressive renal fibrosis in mammals comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a non-peptide CCR1 receptor antagonist.

Abstract: Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Abstract: The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present invention constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound. Examples of the compounds of the present invention are represented by the following chemical structures: wherein: V= NH; O; S; or CH2; R7 is a heterocycle selected from the group consisting of: thiophene; furan; pyrrole; thiazole; pyrazole; imidazole; isoxazole; isothiazole; and 1,3,4-thiadiazole; and Y, A, R1, R2, R3, R4, and n1 are defined herein.

Abstract: The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.

Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

Abstract: A beta-alanine derivative of the formula (I) wherein R1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R2 is hydrogen atom or an amino group which may be substituted with an acyl group; R3 is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.

Abstract: There is provided a compound of formula I, wherein A, D, R1, R2, R3, X and n have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.

Abstract: Compounds of the formula (I), wherein R1 is aryl or biaryl; R2 is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; Y is O, S, SO, SO2, CO or NR6; R3 is hydrogen or lower alkyl; or R2 and R3 combined are C2-C7-alkylene or C2-C7-alkylene interrupted by Y; R4 is hydrogen or lower alkyl; R5 is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; R6 is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitors

Abstract: N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.